NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

March 2, 2026

Study Completion Date

March 2, 2026

Conditions

Non-small Cell Lung Cancer Stage IIIEGFR Positive Non-small Cell Lung CancerNon-squamous Non-small-cell Lung Cancer

Interventions

DRUG

Lazertinib

Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.

Trial Locations (13)

Unknown

RECRUITING

Kosin University Gospel Hospital, Busan

RECRUITING

Keimyung University Dongsan Hospital, Daegu

RECRUITING

Kyungpook National University Medical Center, Daegu

RECRUITING

Chungnam National University Hospital, Daejeon

RECRUITING

Chonnam National University Hospital Hwasun Hospital, Gwangju

RECRUITING

Inha University Hospital, Incheon

RECRUITING

Pusan National University Yangsan Hospital, Pusan

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Hanyang University Seoul Hospital, Seoul

RECRUITING

Koera University Guro Hospital, Seoul

RECRUITING

Korea University Anam Hospital, Seoul

RECRUITING

Kyung Hee University Hospital, Seoul

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors

collaborator

Yuhan Corporation

INDUSTRY

lead

Sung Yong Lee

OTHER